- Report
- November 2023
- 30 Pages
Global
From €2623EUR$2,750USD£2,234GBP
- Report
- July 2018
- 224 Pages
Global
From €1717EUR$1,800USD£1,462GBP
- Report
- June 2022
- 215 Pages
United States
From €2575EUR$2,699USD£2,192GBP
- Report
- June 2021
- 195 Pages
United States
From €2385EUR$2,500USD£2,031GBP
- Report
- October 2019
- 310 Pages
Global
From €3291EUR$3,450USD£2,802GBP
- Report
- June 2019
- 220 Pages
Global
From €2089EUR$2,190USD£1,779GBP
- Report
- April 2023
- 112 Pages
Global
From €4531EUR$4,750USD£3,858GBP
- Report
- June 2021
- 54 Pages
Global
€20988EUR$22,000USD£17,870GBP
- Report
- October 2020
- 51 Pages
Global
€20988EUR$22,000USD£17,870GBP
Fluarix is a vaccine used to protect against influenza, commonly known as the flu. It is a trivalent inactivated vaccine, meaning it contains three different strains of the influenza virus that have been killed. It is administered as an intramuscular injection and is approved for use in adults and children aged three years and older. The vaccine is designed to protect against the most common strains of the virus, and is typically administered annually.
Fluarix is produced by a number of pharmaceutical companies, including GlaxoSmithKline, Sanofi Pasteur, and Seqirus. It is available in many countries around the world, and is widely used in the prevention of influenza. It is also used in combination with other vaccines, such as the pneumococcal vaccine, to provide additional protection against other illnesses. Show Less Read more